Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Vaccine

• Publication date

  2002-11-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0264-410X(02)00444-9PMID 12443660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new approach to the phylogeny ofLeishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages

  2004cited by this paper
• Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).

  2002cited by this paper
• Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis

  2001cited by this paper
• Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

  2001cited by this paper
• Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

  2001cited by this paper
• Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

  2000cited by this paper
• The strange case of Leishmania chagasi.

  2000cited by this paper
• A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

  2000cited by this paper
• Subunit Vaccination of Mice against New World Cutaneous Leishmaniasis: Comparison of Three Proteins Expressed in Amastigotes and Six Adjuvants

  2000influential reference
• Adjuvant and Haemolytic Activities of 47 Saponins Derived from Medicinal and Food Plants

  2000cited by this paper
• The role of phosphoglycans in Leishmania-sand fly interactions.

  2000cited by this paper
• Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.

  2000cited by this paper
• Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission.

  1999cited by this paper
• A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran.

  1999cited by this paper
• Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

  1999cited by this paper
• The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil.

  1999cited by this paper
• Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.

  1999cited by this paper
• Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL‐12 production

  1999cited by this paper
• Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.

  1999cited by this paper
• Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.

  1999cited by this paper
• Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission.

  1998cited by this paper
• Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

  1998cited by this paper
• A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

  1997cited by this paper
• Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.

  1997cited by this paper
• Vaccination with DNA Encoding the Immunodominant LACK Parasite Antigen Confers Protective Immunity to Mice Infected with Leishmania major

  1997cited by this paper
• Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group

  1997cited by this paper
• Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and multiply transfused hemodialysis patients.

  1997cited by this paper
• The logic of visceral leishmaniasis control.

  1996cited by this paper
• Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.

  1995cited by this paper
• Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis.

  1995cited by this paper
• Leishmaniasis research and the European Union

  1995cited by this paper
• A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12

  1995cited by this paper
• Haemolytic Time Course Differences between Steroid and Triterpenoid Saponins

  1995cited by this paper
• Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.

  1995cited by this paper
• Genetic vaccination against leishmaniasis.

  1994cited by this paper
• Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

  1994cited by this paper
• Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML).

  1994influential reference
• Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production.

  1994cited by this paper
• Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.

  1993cited by this paper
• Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML).

  1993cited by this paper
• Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection

  1993cited by this paper
• Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture

  1992cited by this paper
• The Control of the Antibody Isotype Response to Recombinant Human Immunodeficiency Virus gp120 Antigen by Adjuvants

  1992cited by this paper
• Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

  1992cited by this paper
• Double targeted gene replacement for creating null mutants.

  1991cited by this paper
• Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.

  1991influential reference
• The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex.

  1991cited by this paper
• Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.

  1990cited by this paper
• Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses

  1990cited by this paper
• Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands

  1989cited by this paper
• Leishmania infantum, the aetiological agent of American visceral leishmaniasis (AVL)?

  1987cited by this paper
• Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.

  1987cited by this paper
• Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

  1986cited by this paper
• Expression of an unusual acidic glycoconjugate in Leishmania donovani.

  1984cited by this paper
• Leishmania donovani: surface membrane carbohydrates of promastigotes.

  1977cited by this paper
• Infecções experimentaes na Leishmaniose visceral americana

  1938cited by this paper

• Leaf Saponins of Quillaja brasiliensis as Powerful Vaccine Adjuvants

  2025cites this paper
• Exploring a promising vaccine candidate against Leishmania major: Insights from Gp63, LACK, TSA, LmSTI1and KMP11 antigens in BALB/c mice

  2025cites this paper
• The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection

  2025cites this paper
• Unleashing the role of potential adjuvants in leishmaniasis.

  2024cites this paper
• A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites.

  2024cites this paper
• Differential Immune Responses of Th1 Stimulatory Chimeric Antigens of Leishmania donovani in BALB/c Mice.

  2024cites this paper
• Vaccination with Formulation of Nanoparticles Loaded with Leishmania amazonensis Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster

  2023cites this paper
• Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus

  2022cites this paper
• Vaccination approaches for VL

  2021cites this paper
• The role of IL-32 in Bacillus Calmette-Guérin (BCG)-induced trained immunity in infections caused by different Leishmania spp.

  2021cites this paper
• Current status of Leishmania vaccine and problems to be solved

  2021cites this paper
• Vaccination in Leishmaniasis: A Review Article

  2021cites this paper
• Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis

  2020cites this paper
• The Delay in the Licensing of Protozoal Vaccines: A Comparative History

  2020cites this paper
• Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis.

  2020cites this paper
• Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines

  2019cites this paper
• Immunity Regulation by Supramolecular Assemblies

  2019cites this paper
• Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.

  2019cites this paper
• Leishmanicidal Effects of Allium giganteum Saponin-Rich Fraction on Leishmania major

  2019cites this paper
• Antileishmanial and Immunomodulatory Activity of Allium sativum (Garlic)

  2017cites this paper
• Saponaria officinalis L. extract: Surface active properties and impact on environmental bacterial strains.

  2017cites this paper
• Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing

  2016cites this paper
• Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins

  2016cites this paper
• Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.

  2016cites this paper
• Estudo de campo para avaliação da efetividade de vacinação e de uso de coleiras impregnadas com inseticidas para o controle da leishmaniose visceral canina

  2015cites this paper
• Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.

  2015cites this paper
• Immunostimulatory potential and proteome profiling of Leishmania donovani soluble exogenous antigens

  2015cites this paper
• Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection.

  2015cites this paper
• Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis.

  2015cites this paper
• Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.

  2014cites this paper
• IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine

  2014cites this paper
• Visceral Leishmaniasis: Immune Mechanisms and New Insights in Vaccine Development and Control

  2014cites this paper
• Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer

  2013influential citation
• Immunology of Leishmania

  2013cites this paper
• Vaccination as a Control Measure

  2013cites this paper
• Role of imiquimod as adjuvant for vaccination against Leishmania major infection in BALB/c mice

  2013cites this paper
• Vaccines Against Leishmaniasis

  2013cites this paper
• Leishmania and Leishmaniasis

  2013cites this paper
• "DURAÇÃO DA IMUNIDADE VACINAL NA LEISHMANIOSE VISCE RAL CANINA: PADRÃO DE CITOCINAS SINTETIZADAS POR LEUCÓCITOS CIRCULANTES APÓS ESTÍMULO IN VITRO COM ANTÍGENO SOLÚVEL DE Leishmania chagasi "

  2013cites this paper
• Evaluation of novel saponins from Psammosilene tunicoides and their analogs as immunomodulators.

  2012cites this paper
• Characterisation of antibody responses in pigs induced by recombinant oncosphere antigens from Taenia solium.

  2012cites this paper
• Vaccines for Canine Leishmaniasis

  2012cites this paper
• Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.

  2012cites this paper
• Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors

  2012cites this paper
• Vaccine Development Against Leishmania donovani

  2012cites this paper
• Vaccine candidates for leishmaniasis: a review.

  2011cites this paper
• Selection of Adjuvants for Enhanced Vaccine Potency

  2011cites this paper
• AVALIAÇÃO DA RESPOSTA IMUNE EM CAMUNDONGOS UTILIZANDO DIFERENTES PROTOCOLOS DE IMUNIZAÇÃO COM ANTÍGENOS RECOMBINANTES DE Leishmania chagasi

  2011cites this paper
• Selection of Optimal Adjuvants and Product Factors that Affect Vaccine Immunogenicity

  2011cites this paper
• Estudo da imunogenicidade de vacinas de Mycobacterium smegmatis recombinante, expressando o gene que codifica aproteína ácida ribossomal de Leishmania infantum (LiP0), contra a infecção por Leishmania chagasi em hamster

  2011cites this paper
• Vaccine trials against canine leishmaniasis

  2010cites this paper
• Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.

  2010cites this paper
• Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis.

  2010cites this paper
• Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps Its C-Terminal Domain as the Target of the CD4+ T Cell–Driven Protective Response

  2010cites this paper
• Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.

  2010cites this paper
• Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.

  2010cites this paper
• Isolation and evaluation of immunological adjuvant activities of saponins from the roots of Pulsatilla chinensis with less adverse reactions.

  2010cites this paper
• Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.

  2010cites this paper
• KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.

  2009cites this paper
• Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.

  2009cites this paper
• Advances in saponin-based adjuvants.

  2009cites this paper
• Protein‐energy malnutrition decreases immune response to Leishmania chagasi vaccine in BALB/c mice

  2009cites this paper
• Melatonin enhances the immune response to vaccination against A1 and C strains of Dichelobacter nodosus.

  2009cites this paper
• Chapter 63 – Leishmaniasis

  2009cites this paper
• Recent developments in leishmaniasis vaccine delivery systems

  2008cites this paper
• Adjuvant effect of water-soluble polysaccharide (PAP) from the mycelium of Polyporus albicans on the immune responses to ovalbumin in mice.

  2008cites this paper
• FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

  2008cites this paper
• Immunological adjuvant effect of Japanese ginseng saponins (JGS) on specific antibody and cellular response to ovalbumin and its haemolytic activities.

  2008cites this paper
• Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.

  2008cites this paper
• Vaccines for leishmaniasis in the fore coming 25 years.

  2008cites this paper
• Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil

  2008cites this paper
• Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.

  2008cites this paper
• Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

  2008cites this paper
• Haemolytic activities and adjuvant effect of Anemone raddeana saponins (ARS) on the immune responses to ovalbumin in mice.

  2008cites this paper
• A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs

  2007cites this paper
• AVALIAÇÃO DA RESPOSTA IMUNE A VACINAS DE ANTÍGENO PARTICULADO DE Leishmania sp E SUA ASSOCIAÇÃO COM VACINA DE DNA pCI-neo-p36(LACK) EM CAMUNDONGOS BALB/c DESAFIADOS COM Leishmania chagasi

  2007cites this paper
• Ginsenoside Rd elicits Th1 and Th2 immune responses to ovalbumin in mice.

  2007cites this paper
• Assessment of the monoterpene, glycidic and triterpene-moieties' contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis.

  2007cites this paper
• Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

  2007cites this paper
• Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine

  2007influential citation
• Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs

  2007cites this paper
• In vivo and In vitro Control of Leishmania mexicana due to Garlic‐induced NO Production

  2007cites this paper
• Immunological Adjuvant Effect of Ginsenoside Rh4 from the Roots of Panax notoginseng on Specific Antibody and Cellular Response to Ovalbumin in Mice

  2007cites this paper
• Haemolytic activities and adjuvant effect of Bupleurum chinense saponins on the immune responses to ovalbumin in mice.

  2006cites this paper
• Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine.

  2006cites this paper
• Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.

  2006cites this paper
• Structure and biological activity of protopanaxatriol-type saponins from the roots of Panax notoginseng.

  2006cites this paper
• Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice.

  2006cites this paper
• Haemolytic Activity and Adjuvant Effect of Notoginsenoside K from the Roots of Panax notoginseng

  2006cites this paper
• Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge.

  2006cites this paper
• Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice.

  2006cites this paper
• Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection

  2006cites this paper
• Ginsenoside Re and Notoginsenoside R1: Immunologic Adjuvants with Low Haemolytic Effect

  2006cites this paper
• The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.

  2006cites this paper
• Animal models for vaccine studies for visceral leishmaniasis.

  2006cites this paper
• Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.

  2006cites this paper
• Experimental challenge models for canine leishmaniasis in hamsters and dogs, optimization and application in vaccine research

  2006cites this paper
• Heterologous Prime-Boost Vaccination with the LACK Antigen Protects against Murine Visceral Leishmaniasis

  2005cites this paper
• The use of melatonin as a vaccine agent.

  2005cites this paper
• Haemolytic activities and adjuvant effect of Gynostemma pentaphyllum saponins on the immune responses to ovalbumin in mice

  2005influential citation